Neuroflux
Neuroflux provides open-source, AI-powered software that analyzes brain scans to classify tumor type and generate interpretable heatmaps pinpointing tumor boundaries. The platform is designed as lightweight software for low-resource hospitals, and its current version achieves 97.69% accuracy on CT scans for glioblastoma multiforme detection.
- Healthcare Technology
- Digital Health
- Artificial Intelligence
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Glioblastoma multiforme (GBM), one of the most aggressive brain tumors, often goes undetected until advanced stages due to vague early symptoms and diagnostic delays, significantly reducing patient survival rates. Access to AI-powered diagnostic tools is also limited in low-resource hospitals that lack costly computational infrastructure.
Solution
Neuroflux analyzes brain scans, classifies the tumor type, and produces a heatmap highlighting tumor damage, giving doctors clear visual insights for faster decisions. The platform is designed as a lightweight, open-source software to ensure access to AI diagnostics for low-resource hospitals without requiring expensive hardware. Its interpretable heatmaps empower clinicians to verify diagnostic decisions and precisely pinpoint tumor boundaries, enabling safer and more effective treatment planning. The current version is compatible with CT scans, achieving 97.69% accuracy in tumor probability output.
Target Audience
Primary users are radiologists, neurologists, and clinicians in hospital settings, particularly in low-resource environments that need accessible AI-based diagnostic support for brain tumor detection.
Features
- AI-based brain scan analysis that classifies tumor type and outputs tumor probability with 97.69% accuracy on CT scans
- Interpretable heatmap generation that visually pinpoints tumor regions and boundaries for clinical verification
- Open-source, lightweight software architecture optimized for deployment in low-resource hospital settings
- Focus on glioblastoma multiforme (GBM) detection to support earlier diagnosis and improved patient survival outcomes